HHS has not set clear standards or fully enforced policies to prevent conflicts of interest on Medicare pharmacy and therapeutics committees, which decide which therapies should be covered, the HHS Office of Inspector General found. A study published in JAMA Internal Medicine found the same potential conflicts on Medicaid drug panels.

Related Summaries